Navigation Links
Aurobindo Receives Approval from USFDA for anti-AIDS drug

AIDS patients, the world over, can heave a sigh of relief following the nod of approval from the US Food & Drug Administration// (FDA) for the world’s first anti-AIDS cocktail drug for use as a single dose.

The drug manufacturer, Hyderabad-based bulk drugs major Aurobindo Pharma, has made combined anti-retro virals (ARVs) — Retrovir (zidovudine), Epivir (lamivudine) and Viramune (nevirapine) into a single three-in-one fixed dose drug.

The World Health Organisation (WHO) recognizes the three drugs as the first line of therapy for AIDS and they constitute about 50% of drug therapy against the disease.

Therefore the combination of the three drugs as a single tablet will result in fewer dosages as well as side-effects making life much easier for patients. Otherwise these patients have to consume about 20-30 pills a day for the Highly Active Antiretroviral Therapy (HAART) in treating AIDS.

With the US FDA approval means the drug can be sold immediately in over 15 countries as part of the $15 billion US President’s Emergency Plan for AIDS Relief (PEPFAR) programme.

Besides this, since the combination drug has now become a new drug it can receive new drug approval (NDA) and sold in the US markets, once the patents on the individual components expire. The combined market for these three drugs is estimated at a whopping $5 billion annually in the US alone.

The patents for these drugs in the US market expire in 2009 and 2010.

According to Lanka Srinivas, director, Aurobindo Pharma, 'This is indeed a major milestone for Aurobindo and, in fact, the whole country. What is further significant is that this is the first triple combination filing approved by the US FDA and, in fact, the first one ever filed.'

Lanka added that Aurobindo is targeting over $100 million in total revenues from the export of ARVs next year from the current $60 million.


Page: 1

Related medicine news :

1. Aurobindo gets U.S. FDA approval for Cephalexin
2. US FDA approved Aurobindo Pharma to produce generic AIDS drug
3. Aurobindo Gets Tentative USFDA Approval For Its HIV-1 Drug
4. Aurobindo Pharma Purchases US Manufacturing Facility
5. Aurobindo Gets USFDA Approval for Didanosine Chewable Tablets
6. Aurobindo Gets USFDA Approval for A 3-Drug Combination Pack
7. Fifth US Patient Receives Artificial Heart
8. Northfield Labs Receives FDA Comments
9. British MPs Say Prostate Cancer Receives Low Priority in the NHS
10. Abbott Receives CE Mark Certification
11. Zactima Receives Fast Track Designation By The FDA
Post Your Comments:

(Date:6/26/2016)... Carolina (PRWEB) , ... June 26, 2016 , ... ... of a new product that was developed to enhance the health of felines. The ... centuries. , The two main herbs in the PawPaws Cat Kidney Support ...
(Date:6/25/2016)... ... June 25, 2016 , ... Austin residents seeking Mohs surgery services, can ... Surgery and to Dr. Russell Peckham for medical and surgical dermatology. , Dr. Dorsey ... cancer. The selective fellowship in Mohs Micrographic Surgery completed by Dr. Dorsey was under ...
(Date:6/25/2016)... , ... June 25, 2016 , ... As a lifelong ... Cum Laude and his M.D from the David Geffen School of Medicine at UCLA. ... to Los Angeles to complete his fellowship in hematology/oncology at the UCLA-Olive View-Cedars Sinai ...
(Date:6/24/2016)... ... 24, 2016 , ... A recent article published June 14 on ... article goes on to state that individuals are now more comfortable seeking to undergo ... such as calf and cheek reduction. The Los Angeles area medical group, Beverly Hills ...
(Date:6/24/2016)... , ... June 24, 2016 , ... ... and Scientific Sessions in Dallas that it will receive two significant new grants ... grants came as PHA marked its 25th anniversary by recognizing patients, medical professionals ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... 2016 Capricor Therapeutics, Inc. ... biotechnology company focused on the discovery, development and ... enrollment in its ongoing randomized HOPE-Duchenne clinical trial ... of its 24-patient target. Capricor expects the trial ... of 2016, and to report top line data ...
(Date:6/23/2016)... BOGOTA, Colombia , June 23, 2016  Astellas today announced the establishment of Astellas Farma Colombia (AFC), a ... second affiliate in Latin America . ... ... ... ...
(Date:6/23/2016)... 23, 2016  Experian Health, the healthcare ... the patient payment and care experience, today ... products and services that will enhance the ... offerings. These award-winning solutions will enable healthcare ... compliant in an ever-changing environment and redefine ...
Breaking Medicine Technology: